137 related articles for article (PubMed ID: 32397829)
1. Structure-based virtual screening, biological evaluation and biophysical study of novel Mcl-1 inhibitors.
Du J; Liu L; Liu B; Yang J; Hou X; Yu J; Fang H
Future Med Chem; 2020 Jul; 12(14):1293-1304. PubMed ID: 32397829
[No Abstract] [Full Text] [Related]
2. Discovery of novel indazole-acylsulfonamide hybrids as selective Mcl-1 inhibitors.
Wan Y; Li Y; Yan C; Wen J; Tang Z
Bioorg Chem; 2020 Nov; 104():104217. PubMed ID: 32911192
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.
Liu L; Liu R; Yang X; Hou X; Fang H
Eur J Med Chem; 2020 Apr; 191():112142. PubMed ID: 32088497
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
Wan Y; Wang J; Sun F; Chen M; Hou X; Fang H
Bioorg Med Chem; 2015 Dec; 23(24):7685-93. PubMed ID: 26620718
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, stereochemical determination, molecular docking study, in silico pre-ADMET prediction and anti-proliferative activities of indole-pyrimidine derivatives as Mcl-1 inhibitors.
Lamie PF; Philoppes JN
Bioorg Chem; 2021 Nov; 116():105335. PubMed ID: 34509795
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
Niu Q; Deng H; Zhang Z; Xu Q; Luan S; Huang M; Liu D; Zhao L
Bioorg Med Chem Lett; 2021 Sep; 47():128215. PubMed ID: 34153472
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoprotein.
Lanning ME; Yu W; Yap JL; Chauhan J; Chen L; Whiting E; Pidugu LS; Atkinson T; Bailey H; Li W; Roth BM; Hynicka L; Chesko K; Toth EA; Shapiro P; MacKerell AD; Wilder PT; Fletcher S
Eur J Med Chem; 2016 May; 113():273-92. PubMed ID: 26985630
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design, synthesis, and evaluation of Bcl-2/Mcl-1 dual inhibitors.
Zhu J; Wang Z; Guo Z; Zhang X; Song T; Guo Y; Ji T; Zhang Z
Arch Pharm (Weinheim); 2020 May; 353(5):e2000005. PubMed ID: 32175625
[TBL] [Abstract][Full Text] [Related]
9. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N; Matulis SM; Koss B; Fischer MA; Arnold AL; Camper DV; Browning CF; Rossanese OW; Budhraja A; Opferman J; Boise LH; Savona MR; Letai A; Olejniczak ET; Fesik SW
FEBS Lett; 2017 Jan; 591(1):240-251. PubMed ID: 27878989
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Optimization of 3-Phenyl-
Li Y; Fan W; Gong Q; Tian J; Zhou M; Li Q; Uwituze LB; Zhang Z; Hong R; Wang R
J Med Chem; 2021 Jul; 64(14):10260-10285. PubMed ID: 34228434
[TBL] [Abstract][Full Text] [Related]
11. Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.
Wan Y; Liu T; Li X; Chen C; Fang H
Bioorg Med Chem; 2017 Jan; 25(1):138-152. PubMed ID: 27810438
[TBL] [Abstract][Full Text] [Related]
12. 1-Phenyl-1H-indole derivatives as a new class of Bcl-2/Mcl-1 dual inhibitors: Design, synthesis, and preliminary biological evaluation.
Xu G; Liu T; Zhou Y; Yang X; Fang H
Bioorg Med Chem; 2017 Oct; 25(20):5548-5556. PubMed ID: 28866374
[TBL] [Abstract][Full Text] [Related]
13. Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates.
Drennen B; Scheenstra JA; Yap JL; Chen L; Lanning ME; Roth BM; Wilder PT; Fletcher S
ChemMedChem; 2016 Apr; 11(8):827-33. PubMed ID: 26844930
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of hydantoin derivatives as Mcl-1 selective inhibitors.
Liang X; Li X; Zhao Z; Nie Y; Yao Z; Ren W; Yang X; Hou X; Fang H
Bioorg Chem; 2022 Apr; 121():105643. PubMed ID: 35150958
[TBL] [Abstract][Full Text] [Related]
15. Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL-1.
Daressy F; Malard F; Seguy L; Guérineau V; Apel C; Dumontet V; Robert A; Groo AC; Litaudon M; Bignon J; Desrat S; Malzert-Fréon A; Wiels J; Lescop E; Roussi F
ChemMedChem; 2021 Jun; 16(11):1788-1797. PubMed ID: 33665938
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
Wan Y; Dai N; Tang Z; Fang H
Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
[TBL] [Abstract][Full Text] [Related]
17. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1).
Beekman AM; O'Connell MA; Howell LA
ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 3,5-Dimethyl-4-Sulfonyl-1
Zhu PJ; Yu ZZ; Lv YF; Zhao JL; Tong YY; You QD; Jiang ZY
J Med Chem; 2021 Aug; 64(15):11330-11353. PubMed ID: 34342996
[TBL] [Abstract][Full Text] [Related]
19. Discovery and structure-activity relationship studies of N-substituted indole derivatives as novel Mcl-1 inhibitors.
Luan S; Ge Q; Chen Y; Dai M; Yang J; Li K; Liu D; Zhao L
Bioorg Med Chem Lett; 2017 May; 27(9):1943-1948. PubMed ID: 28343875
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors.
Li R; Cheng C; Balasis ME; Liu Y; Garner TP; Daniel KG; Li J; Qin Y; Gavathiotis E; Sebti SM
Eur J Med Chem; 2015 Jan; 90():315-331. PubMed ID: 25437618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]